Internalization of microparticles by platelets is partially mediated by toll-like receptor 4 and enhances platelet

Didac Jerez-Dolz1, Sergi Torramade-Moix1, Marta Palomo2

  • 1Hematopathology, Pathological Anatomy, Hospital Clinic of Barcelona, Biomedical Diagnosis Centre (CDB), Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

Atherosclerosis
|January 17, 2020
PubMed
Abstract

Insights

Platelets internalize circulating platelet microparticles (PMP), increasing blood clot formation. This process involves toll-like receptor 4 (TLR-4) and can be inhibited by blocking TLR-4, suggesting a therapeutic target for thrombotic events.

Area of Science:

  • Hematology
  • Immunology
  • Cell Biology

Background:

  • Circulating platelet microparticles (PMP) are abundant, procoagulant, and interact with inflammatory cells.
  • Understanding PMP interactions with platelets is crucial for comprehending thrombotic and inflammatory processes.

Purpose of the Study:

  • To investigate the interaction between platelet microparticles (PMP) and platelets.
  • To explore the role of toll-like receptor 4 (TLR-4) in PMP-platelet interactions.

Main Methods:

  • PMP were isolated from expired platelet concentrates.
  • PMP were incubated with washed platelets, platelet-rich plasma, and whole blood.
  • Techniques included flow cytometry, electron microscopy, aggregometry, and thromboelastometry (ROTEM); anti-TLR-4 antibody was used to assess inhibition.

Main Results:

  • Platelets internalized PMP, confirmed by microscopy and flow cytometry.
  • PMP increased heterotypic aggregate formation, platelet aggregation, and accelerated clotting times.
  • Inhibition of TLR-4 reduced PMP-platelet association, prevented aggregate formation, and normalized clotting parameters.

Conclusions:

  • Platelets internalize their own PMP, enhancing thrombogenicity.
  • This internalization process is partly mediated by the innate immunity receptor TLR-4.
  • Targeting TLR-4 may offer a strategy to mitigate PMP-induced thrombotic events.

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.7K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.5K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
990
Inflammation01:38

Inflammation

Overview
61.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K